Gwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, Elizabeth L Christie, Dale W Garsed, Elizabeth Lieschke, Ksenija Nesic, Olga Kondrashova, Gayanie Ratnayake, Marc Radke, Jocelyn S Penington, Amandine Carmagnac, Valerie Heong, Elizabeth L Kyran, Fan Zhang, Nadia Traficante, Ruby Huang, Alexander Dobrovic, Elizabeth M Swisher, Orla McNally, Damien Kee, Matthew J Wakefield, Anthony T Papenfuss, David D L Bowtell, Holly E Barker, Clare L Scott
BACKGROUND: Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have de novo platinum-refractory disease. OBJECTIVES: To determine the potential of anti-microtubule agent (AMA) therapy (paclitaxel, vinorelbine and eribulin) in platinum-resistant or refractory (PRR) HGSC by assessing response in patient-derived xenograft (PDX) models of HGSC...
2023: Therapeutic Advances in Medical Oncology